Xtx Topco LTD Fate Therapeutics Inc Transaction History

Xtx Topco LTD

$1.13 Billion
Q4 2024

A detailed history of Xtx Topco LTD transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Xtx Topco LTD holds 249,800 shares of FATE stock, worth $252,298. This represents 0.04% of its overall portfolio holdings.

Number of Shares

249,800

Holding current value

$252,298

% of portfolio

0.04%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$1.61 - $3.35 $402,178 - $836,830	249,800 New	249,800 $412,000
Q2 2024 Aug 12, 2024	BUY	$3.26 - $7.08 $53,822 - $116,890	16,510 Added 94.95%	33,898 $111,000
Q1 2024 May 13, 2024	BUY	$3.54 - $8.35 $61,553 - $145,189	17,388 New	17,388 $127,000
Q3 2023 Nov 13, 2023	BUY	$2.02 - $5.04 $346,068 - $863,457	171,321 Added 793.19%	192,920 $408,000
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $31,373 - $43,434	-6,591 Reduced 23.38%	21,599 $102,000
Q1 2023 May 12, 2023	SELL	$4.24 - $11.12 $322,240 - $845,119	-76,000 Reduced 72.94%	28,190 $160,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $824,986 - $1.99 Million	83,670 Added 407.75%	104,190 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $431,740 - $739,951	20,520 New	20,520 $460,000
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $298,661 - $482,383	-5,039 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $338,872 - $466,208	5,039 New	5,039 $437,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

Redmile Group, LLC San Francisco, CA

12.9M
Shares

$13 Million
1.66% of portfolio
Vanguard Group Inc Valley Forge, PA

10.3M
Shares

$10.4 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$10.2 Million
0.0% of portfolio
Bellevue Group Ag Kuesnacht, V8

4.84M
Shares

$4.89 Million
0.16% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

4.38M
Shares

$4.43 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $98M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account